Security

INDV

Indivior Pharmaceuticals Inc. · COM

CUSIP 45579U109 Equity holders as of 2026 Q1 (each manager’s latest book)

grid → activity →
owners 7
max % 3.3%
tracked value $473M
qoq N 7 A 0 R 0

holders

sorted by % of portfolio · long equity only

manager % port activity shares value history
Howard Marks - Oaktree Capital Management LP 2026 Q1 3.3% New 3.3% 6,984,102 $213M hist
Israel Englander - Millennium Management LLC 2026 Q1 0.1% New 0.1% 4,595,535 $140M hist
Ken Griffin - Citadel Advisors LLC 2026 Q1 0.0% New 0.0% 3,574,044 $109M hist
Ray Dalio - Bridgewater Associates, LP 2026 Q1 0.0% New 0.0% 37,141 $1M hist
D. E. Shaw & Co., Inc. 2026 Q1 0.0% New 0.0% 203,985 $6M hist
Steve Cohen - Point72 Asset Management, L.P. 2026 Q1 0.0% New 0.0% 94,943 $3M hist
Natixis Advisors, LLC 2026 Q1 0.0% New 0.0% 21,782 $664 hist

7 tracked managers · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

line FY2024 FY2025
Revenue $1.19B $1.24B
Gross profit $957M $994M
Gross margin * 80.6% 80.2%
Net income $2M $210M
Net margin * 0.2% 16.9%

Balance sheet

line FY2024 FY2025
Total current assets $839M $652M
Total non-current assets * $480M $549M
Total assets $1.32B $1.2B
Total current liabilities $939M $914M
Total non-current liabilities * $729M $386M
Total equity -$348M -$98M

Cash flow

line FY2024 FY2025
Cash from operations $36M -$27M
Cash from investing $69M -$66M
Cash from financing -$102M -$30M
Net change in cash * $3M -$123M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings · CIK 0001625297

ownership over time

filing count by report period · click a bar for that quarter’s holders

26Q1

period archive